CAS: 2088323-16-2; (R)-1-(1-Acryloylpiperidin-3-yl)-4-Amino-N-(4-(2-(Dimethylamino)-2-Oxoethyl)-2,3-Dimethylphenyl)-1H-Pyrazolo[3,4-D]Pyrimidine-3-Carboxamide

主要参考文献

1: Piha-Paul SA, Azaro A, Arkenau HT, Oh DY, Galsky MD, Pal SK, Hamada K, He Y, Yamamiya I, Benhadji KA, Hollebecque A. A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. Invest New Drugs. 2021 Mar 27. doi: 10.1007/s10637-021-01104-7. Epub ahead of print. 111(6):2123-2131. doi: 10.1111/cas.14407. Epub 2020 Apr 30.
3: Irie H, Ito K, Fujioka Y, Oguchi K, Fujioka A, Hashimoto A, Ohsawa H, Tanaka K, Funabashi K, Araki H, Kawai Y, Shimamura T, Wadhwa R, Ohkubo S, Matsuo K. TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2019 Apr;18(4):733-742. doi: 10.1158/1535-7163.MCT-18-1085. Epub 2019 Feb 20.